TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01838590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03148106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensory Electrical Stimulation
Description: We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
Study: NCT01567891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYESO-1c259 T cells
Description: Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
Study: NCT04240106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib orally daily beginning on Day 1 and continuing through Day 28 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Aromatase Inhibitors beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study: NCT03938818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tu'Washindi intervention
Description: The intervention includes the following components:~1. PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~2. Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~3. Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
Study: NCT00114127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine 1x per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine 1x per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60 mg duloxetine 1x per day + 60mg duloxetine 1x per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60mg placebo 1x per day
Study: NCT00224081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate,
Description: Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
Study: NCT01828918

Intervention type: GENETIC
Group type: OTHER
Intervention: microRNAs
Study: NCT01916707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dosing of enoxaparin for VTE prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing of enoxaparin for VTE prophylaxis
Study: NCT01446679

Intervention type: DRUG
Intervention: atrovastatin
Description: oral
Study: NCT01116687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given orally
Study: NCT00421148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg/kg
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 1 mg/kg
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium bromide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: IV infusion
Study: NCT05834985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
Description: endoscopic management of fistula due to sigmoid diverticulitis by clip or endostitches
Study: NCT03222674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Description: Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
Study: NCT04005586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Delivery Device (LDD)
Description: Study eye will undergo Light delivery Device treatments
Study: NCT04224922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study: NCT01116687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03345940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
Study: NCT04224922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT00761982

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Infusion on autologous CD34+ stem cells into middle cerebral artery
Description: Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
Study: NCT01762878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
Study: NCT03345940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethyl Fumarate
Description: Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
Study: NCT06580860

Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Study: NCT01762878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder for oral inhalation once daily using DIKUS device
Study: NCT00981643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation instruction and practice
Description: Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation instruction and practice
Description: Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
Study: NCT06580860

Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.

Intervention type: DRUG
Intervention: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
Description: Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
Study: NCT03351569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Intravenous drip.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: Intravenous drip.
Study: NCT01664858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3T CMR
Description: 3Tesla Cardiac Magnetic Resonance Imaging
Study: NCT01436799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: anaesthesia was maintained by desflurane 4-7vol%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfentanil
Description: administration of alfentanil 10 μg kg-1 for anesthetic induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfentanil
Description: administration of alfentanil 10 μg kg-1 for anesthetic induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: administration of rocuronium 0.6 mg kg-1 for anesthetic induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: administration of rocuronium 0.6 mg kg-1 for anesthetic induction
Study: NCT01907126

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Program (NP)
Description: Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's Prison CoOp (WPC)
Description: Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
Study: NCT03693573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
Study: NCT01881113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 2 separate times during a 14 day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT05154812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng Jie Du therapy
Description: Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care
Study: NCT06458842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01155024

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional fabricated prosthetic socket
Description: A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional fabricated prosthetic socket
Description: A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.

Intervention type: DEVICE
Group type: OTHER
Intervention: Direct manufactured (DM) prosthetic socket
Description: A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)

Intervention type: DEVICE
Group type: OTHER
Intervention: Direct manufactured (DM) prosthetic socket
Description: A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
Study: NCT05555563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTAD irrigation
Description: Final irrigation protocol was performed using 5 ml MTAD (n=50).
Study: NCT00861198

Intervention type: OTHER
Intervention: ERCP as per medical indication
Description: ERCP as per medical indication
Study: NCT01345435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Description: The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring & Telemedicine
Description: The Telemonitoring \& Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.

Intervention type: OTHER
Group type: OTHER
Intervention: SMBG
Description: The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
Study: NCT04619992

Intervention type: DEVICE
Group type: OTHER
Intervention: Currently marketed Hydrophillic Intermittent Catheter
Description: Currently marketed Hollister standard with tip hydrophilic intermittent catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Test Hydrophilic Intermittent Catheter
Description: Hollister standard with tip hydrophilic intermittent catheter with design enhancements

Intervention type: DEVICE
Group type: OTHER
Intervention: Test Hydrophilic Intermittent Catheter
Description: Hollister standard with tip hydrophilic intermittent catheter with design enhancements
Study: NCT00739986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: semapimod 60 mg IV x 1 day, placebo x 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semapimod
Description: Semapimod 60 mg IV x 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo IV x 3 days
Study: NCT00967044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
Study: NCT02440113

Intervention type: DEVICE
Intervention: Nellix
Description: Nellix Implantation
Study: NCT01350843

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange Juice
Description: 250ml of orange juice or a sugars matched orange drink daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange Juice
Description: 250ml of orange juice or a sugars matched orange drink daily
Study: NCT04276844

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography using the two-dimensional (2D) mode
Description: Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography using the two-dimensional (2D) mode
Description: Diaphragmatic amplitude assessed by ultrasonography during quiet breathing and after sniff test, before the surgery and at day 7 post-surgery in all patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory Functional Explorations
Description: Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV) and total lung capacity (TLC) measured at day 7
Study: NCT00468728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAR-101/OPT-80
Description: capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Capsules
Study: NCT02244918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Study: NCT03386565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride solution
Description: intraoperative IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intraoperative IV infusion
Study: NCT02754908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical training
Description: The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: tutoring classes
Description: They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
Study: NCT03178526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin gel
Description: Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo gel
Study: NCT02893202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback riding
Description: An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback riding
Description: An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
Study: NCT01664858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPECT
Description: SPECT: Single Photon Emission Computed Tomography